Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Cristina Pirosa

Showing results (11-20 of 34) with videos related to

Pageof 4
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 17, 2025
PET-Based Risk Stratification in Primary Mediastinal B-Cell Lymphoma: A Comparative Analysis of Different Segmentation Methods in the IELSG37 Trial Patient CohortLuca Ceriani, Lisa Milan, Maria Cristina Pirosa, et al.
British Journal of Haematology|August 7, 2019
Late relapse in patients with diffuse large B-cell lymphoma: impact of rituximab on their incidence and outcomeBarbara Vannata, Annarita Conconi, Jonas Winkler, et al.
Cancers|June 12, 2026
A Phase Ib Trial of Copanlisib in Combination with Venetoclax in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma-SAKK 66/18 TrialMaria Cristina Pirosa, Dagmar Hess, Fatime Krasniqi, et al.
Chemotherapy|October 30, 2018
Long-Term Molecular Remission Achieved by Antibody Anti-CD22 and Ponatinib in a Patient Affected by Ph'+ Acute Lymphoblastic Leukemia Relapsed after Second Allogeneic Hematopoietic Stem Cell Transplantation: A Case ReportMaria Cristina Pirosa, Salvatore Leotta, Alessandra Cupri, et al.
Hematological Oncology|September 26, 2024
Superior prognostic accuracy of FIGO staging system in primary female genital tract lymphomas: A retrospective study (IELSG35)Maria Cristina Pirosa, Sara Steffanoni, Anna Vanazzi, et al.
British Journal of Haematology|October 19, 2023
Baseline circulating tumour DNA and interim PET predict response in relapsed/refractory classical Hodgkin lymphomaEleonora Calabretta, Martina di Trani, Francesco Corrado, et al.
Expert Review of Molecular Diagnostics|May 1, 2018
PMN-MDSC and arginase are increased in myeloma and may contribute to resistance to therapyAlessandra Romano, Nunziatina Laura Parrinello, Piera La Cava, et al.
Hematological Oncology|October 29, 2021
Generation and validation of a PET radiomics model that predicts survival in diffuse large B cell lymphoma treated with R-CHOP14: A SAKK 38/07 trial post-hoc analysisLuca Ceriani, Lisa Milan, Luciano Cascione, et al.
Cancers|February 25, 2022
Integration of Baseline Metabolic Parameters and Mutational Profiles Predicts Long-Term Response to First-Line Therapy in DLBCL Patients: A Post Hoc Analysis of the SAKK38/07 StudySofia Genta, Guido Ghilardi, Luciano Cascione, et al.
Blood Advances|March 21, 2020
SAKK38/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic modelLuca Ceriani, Giuseppe Gritti, Luciano Cascione, et al.
Pageof 4

Showing results (11-20 of 34) with videos related to

Sort By:
Pageof 4
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 17, 2025
PET-Based Risk Stratification in Primary Mediastinal B-Cell Lymphoma: A Comparative Analysis of Different Segmentation Methods in the IELSG37 Trial Patient CohortLuca Ceriani, Lisa Milan, Maria Cristina Pirosa, et al.
British Journal of Haematology|August 7, 2019
Late relapse in patients with diffuse large B-cell lymphoma: impact of rituximab on their incidence and outcomeBarbara Vannata, Annarita Conconi, Jonas Winkler, et al.
Cancers|June 12, 2026
A Phase Ib Trial of Copanlisib in Combination with Venetoclax in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma-SAKK 66/18 TrialMaria Cristina Pirosa, Dagmar Hess, Fatime Krasniqi, et al.
Chemotherapy|October 30, 2018
Long-Term Molecular Remission Achieved by Antibody Anti-CD22 and Ponatinib in a Patient Affected by Ph'+ Acute Lymphoblastic Leukemia Relapsed after Second Allogeneic Hematopoietic Stem Cell Transplantation: A Case ReportMaria Cristina Pirosa, Salvatore Leotta, Alessandra Cupri, et al.
Hematological Oncology|September 26, 2024
Superior prognostic accuracy of FIGO staging system in primary female genital tract lymphomas: A retrospective study (IELSG35)Maria Cristina Pirosa, Sara Steffanoni, Anna Vanazzi, et al.
British Journal of Haematology|October 19, 2023
Baseline circulating tumour DNA and interim PET predict response in relapsed/refractory classical Hodgkin lymphomaEleonora Calabretta, Martina di Trani, Francesco Corrado, et al.
Expert Review of Molecular Diagnostics|May 1, 2018
PMN-MDSC and arginase are increased in myeloma and may contribute to resistance to therapyAlessandra Romano, Nunziatina Laura Parrinello, Piera La Cava, et al.
Hematological Oncology|October 29, 2021
Generation and validation of a PET radiomics model that predicts survival in diffuse large B cell lymphoma treated with R-CHOP14: A SAKK 38/07 trial post-hoc analysisLuca Ceriani, Lisa Milan, Luciano Cascione, et al.
Cancers|February 25, 2022
Integration of Baseline Metabolic Parameters and Mutational Profiles Predicts Long-Term Response to First-Line Therapy in DLBCL Patients: A Post Hoc Analysis of the SAKK38/07 StudySofia Genta, Guido Ghilardi, Luciano Cascione, et al.
Blood Advances|March 21, 2020
SAKK38/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic modelLuca Ceriani, Giuseppe Gritti, Luciano Cascione, et al.
Pageof 4